Rob High, CTO of IBM Watson and Jho Low, CEO of Jynwel Capital recently shared their thoughts on Watson’s potential to drastically improve cancer care with Scientific American. The pair wrote, “Cutting-edge cancer therapies garner headlines, and one has to marvel at the advances in oncology research achieved over the past decade. Unfortunately, relatively few patients have access to advanced treatment plans at specialized cancer centers such as MD Anderson. Most receive far less effective cancer care, or no care at all. In addition, even the most devoted specialists cannot keep up with the ever-expanding body of medical literature. To fill these healthcare gaps, doctors and computer scientists at MD Anderson developed the MD Anderson Oncology Expert Advisor™ cognitive clinical decision support system (OEA™) [powered by Watson], which is being brought to life with the support of a $50 million gift from Jynwel Charitable Foundation to MD Anderson’s Moon Shots program.” Read more
Posts Tagged ‘MD Anderson’
The role that cognitive computing can play in healthcare was explored last week in this story published at The Semantic Web Blog’s sister site Dataversity.net. That article looked at how Modernizing Medicine is leveraging IBM Watson for its new schEMA tablet app that helps doctors use the wealth of published medical research from highly reputable sources, such as the Journal of the American Medical Association (JAMA) and New England Journal of Medicine, to answer their questions.
Today, we’re complementing that article to further explore such aspects of the health care and cognitive computing connection based on an email conversation with IBM Watson Group CTO Robert High. “IBM Watson is transforming the patient experience and healthcare delivery system by helping physicians make sense of the enormous amount of data generated by an increasingly connected healthcare environment,” High writes.
“Content curation is a critical part of the solution delivery process. Without reputable and reliable sources of medical literature, therapy choices offered by Watson may not have the supporting evidence needed to inform clinicians in the use of those treatments. We work with the top clinicians at our partners to collect their feedback on supporting evidence and cull inappropriate information from their sources.” IBM, along with its solutions partners, works with a variety of content providers based on the relevance of their materials to treatment options, he adds.